Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma.

MLA

LeBlanc, R., et al. “Updates from the 2019 American Society of Clinical Oncology and European Hematology Association Annual Meetings: A Canadian Perspective on High-Risk Cytogenetics in Multiple Myeloma.” Current Oncology, vol. 26, no. 4, Aug. 2019, pp. e581–94. EBSCOhost, https://doi.org/10.3747/co.26.5565.

APA

LeBlanc, R., Song, K., White, D., Christofides, A., & Doucette, S. (2019). Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma. Current Oncology, 26(4), e581–e594. https://doi.org/10.3747/co.26.5565

Chicago

LeBlanc, R., K. Song, D. White, A. Christofides, and S. Doucette. 2019. “Updates from the 2019 American Society of Clinical Oncology and European Hematology Association Annual Meetings: A Canadian Perspective on High-Risk Cytogenetics in Multiple Myeloma.” Current Oncology 26 (4): e581–94. doi:10.3747/co.26.5565.